Zitat:"LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration (DEA). EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs)...." ENDE Zitat
Quelle:https://www.stockwatch.com/News/...80927&symbol=GWPH&region=U  

DEA permits GW Pharma to sell cannabis derived drug, CEO says there is...

https://www.cnbc.com/video/2018/09/27/...e-need-for-the-medicine.html
 

Zitat:"GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, announced today that results from completed Phase 3 trials of EPIDIOLEX® (cannabidiol) oral solution CV, as well as new pre-clinical and Phase 1 cannabinoid research, will be presented at the American Epilepsy Society (AES) Annual Meeting, November 30-December 4, 2018, in New Orleans, Louisiana. EPIDIOLEX is FDA-approved and available by prescription in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older...." ENDE Zitat
Quelle:https://www.stockwatch.com/News/...81119&symbol=GWPH&region=U  

Important Safety Information & Indications
What is the Most Important Information I Should Know About EPIDIOLEX?
Do not take if you are allergic to cannabidiol or any of the ingredients in EPIDIOLEX.
EPIDIOLEX may cause liver problems. Your doctor may order blood tests to check your liver before you start taking EPIDIOLEX and during treatment. In some cases, EPIDIOLEX treatment may need to be stopped. Call your doctor right away if you start to have any of these signs and symptoms of liver problems during treatment with EPIDIOLEX:

   loss of appetite, nausea, vomiting
   fever, feeling unwell, unusual tiredness
   yellowing of the skin or the whites of the eyes (jaundice)
   itching
   unusual darkening of the urine
   right upper stomach area pain or discomfort

EPIDIOLEX may cause you to feel sleepy, which may get better over time. Other medicines (e.g., clobazam) or alcohol may increase sleepiness. Do not drive, operate heavy machinery, or do other dangerous activities until you know how EPIDIOLEX affects you.

Like other antiepileptic drugs, EPIDIOLEX may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.

Quelle:https://www.stockwatch.com/News/...81119&symbol=GWPH&region=U  

https://www.stockwatch.com/Chart/...me=5&symbol=GWPH&region=U  

Zitat:"CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).  Results for both the 25 and 50 mg/kg/day dose groups were similar, with seizure reductions of 48.6% and 47.5% from baseline respectively, vs 26.5% for placebo (50 mg/kg/day vs placebo, p=0.0018). All key secondary endpoints were supportive of the effects on the primary endpoint. The safety profile observed is consistent with findings from previous studies, with no new safety risks identified.......“The positive outcome in this trial of EPIDIOLEX in patients with Tuberous Sclerosis Complex expands both our knowledge of this newly available medicine and its potential utility beyond the current indications,”...ENDE Zitat
Quelle:https://www.otcmarkets.com/stock/GWPH/news/story?e&id=1349254
 

https://www.stockwatch.com/Chart/...me=5&symbol=GWPH&region=U  

https://www.stockwatch.com/Chart/...me=1&symbol=GWPH&region=U

 

Hat jemand in diesem Thread Musse oder vielleicht im Tagesgeschäft genug Langeweile um mir zu erklären was das Chart zu bedeuten hat? Ich bin Anfängerin und charts sind für mich noch sehr schwer zu verstehen. obwohl ich nichts verstehe bin ich investiert.
Lieben Dank im Voraus  

Quelle:https://www.stockwatch.com/Chart/...me=1&symbol=GWPH&region=U

 

..sorry für das Gekritzel

... im Nachfolgenden Link / Bericht , lässt sich das Gap im Oktober 2016 (aus meiner Sicht) gut erkennen.

https://www.newcannabisventures.com/...arma-acquisition-price-of-349/

....      : "Jedes Gap wird irgendwann einmal geschlossen..."  

https://www.analystratings.com/articles/...ences-sgmo-gw-pharma-gwph/  

 

https://www.stockwatch.com/Chart/...me=1&symbol=GWPH&region=U

IMO sollten die zwei innert kürzester Zeit generierten Up-Gap ( bei 108,- und im Bereich von 118,00 / 125,00 )nicht in Vergessenheit geraten, .....daher erlaube ich mir dies hier kurz mittels Chartbild (1-Year) als Reminder zu dokumentieren....  

Zahlen für 2019

• Umsatz 311 Mio. $ (davon 109 in Q4)
  
• Verlust 9 Mio. $ (davon 25 in Q4)
  
• Cash 537 Mio. $
  
• MK 3,56 Mrd. $
  

http://ir.gwpharm.com/news-releases/...urth-quarter-and-year-end-2019

 

• MK 2,43 Mrd. $
  

https://www.fool.com/investing/2020/03/06/...plunged-in-february.aspx

 

neues 52 WT  

GW Pharmaceuticals ADR Forum
                                        §
88,31 $ +13,42 $
In : 81,872 € | 15:43:27 Uhr Nasdaq
https://www.ariva.de/gw_pharmaceuticals_adr-aktie  

Zitat:Greenwich Biosciences, Inc., announced today that it has received notification from the United States Drug Enforcement Administration (DEA) confirming that EPIDIOLEX® (cannabidiol) is no longer subject to the Controlled Substances Act (CSA).  This change takes effect immediately.....“This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act,” said Justin Gover, GW’s Chief Executive Officer.  “We would like to thank DEA for confirming the non-controlled status of this medicine. " ENDE Zitat
Source:https://www.stockwatch.com/News/...00406&symbol=GWPH&region=U  

Epidiolex Umsätze in Q1/20

• 120,6 Mio. $ (+209% zum VJQ)
  
• Markterwartungen für den Umsatz lagen bei ~108 Mio. $
  

http://ir.gwpharm.com/news-releases/...s-first-quarter-2020-financial

 

Zitat:"LONDON, June 24, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the UK Home Office has reclassified EPIDYOLEX (cannabidiol) as a Schedule 5 drug. This change will take effect immediately in all four of the constituent nations of the UK – with Northern Ireland enacting separate legislation1 – and sees the medicine move from Schedule 2 to Schedule 5 under the Misuse of Drugs Regulations 2001.................“The decision to move EPIDYOLEX to a low level of control is an important one for patients, their families, healthcare professionals, pharmacists and the NHS as a whole – reducing costs and ensuring the medicine can be dispensed more easily,” said Chris Tovey, GW’s Chief Operating Officer. ..... " ENDE Zitat


Quelle:https://www.stockwatch.com/News/...00623&symbol=GWPH&region=U  

Zitat:"2020-07-23 07:00 ET - News Release........GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020 ......" Ende Zitat
Quelle/Source:https://www.stockwatch.com/News/...00723&symbol=GWPH&region=U

 

vorab... bin kein guter Zeichner,..daher sind vlt die Linien nicht exakt...aber für einen groben Überblick und zur Meinungsbildung ggf auschreichend..

Sowohl der 3-Y Chart, wie auch die heutige Analystenmeldung (IMO...wenn die anfangen was zu schreiben, von dem man ja als langfristig orientierter Anleger eh schon informationstechnisch Kentniss hat..... vlt mal genauer hinschauen)  und die für in einer Woche (06.August 2020) angekündigte Conference-Call,... veranlassten mich, mal wieder etwas genauer hinzusehen....

Link1 (Analysten-Meinung/Meldung):https://www.ariva.de/news/...oraus-sehen-wir-hier-die-neue-gw-8615178

Link2 ( GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 2020): https://www.stockwatch.com/News/...GWPH-20200723&symbol=GWPH&
region=U

Link3 (Quelle Chart-Anmeldung erforderlich):https://www.tradesignalonline.com/chart/

 

p.s. sollten die Linien komplett falsch angesetzt sein,.. gerne freue ich mich über eine BM und lasse mir das mal etwas erklären... THX  

Zahlen für Q2/2020

• Epidiolex-Umsätze 118 Mio. $
  

https://ir.gwpharm.com/news-releases/...second-quarter-2020-financial